Top Tweets for #TORIPALIMAB
Another promising activity w/ nectin 4 ADC- #BulumtatugFuvedotin (9MW2821) + #toripalimab showed promising activity in phase I/II for aUC- ORR 83%, CR 12.8%, median PFS 12.9 mo; mOS & mDOR NR. Responses seen across subgroups, including elderly & renal-impaired pts #ASCO26
メラノーマに対するtoripalimabの有効性。進行末端黒子型メラノーマの一次治療としてのPD-1阻害薬toripalimabの有効性と安全性をダカルバジンと比較したところ、無増悪生存（PFS）はtoripalimab群で有意に延長しました。https://t.co/wP4uGOzoJ2 #薬剤師 #進行末端黒子型メラノーマ #toripalimab
🌟 #Disitamab Vedotin + #Toripalimab in #HER2-Expressing Advanced Urothelial Cancer
NEJM, Oct 2025 RC48-C016🌟
🔶 Phase III trial in previously untreated HER2-expressing (IHC 1+/2+/3+) locally advanced or metastatic urothelial cancer
🔶 PFS doubled vs chemotherapy: 13.1 vs 6.5 months (HR 0.36; P<0.001)
🔶 Overall survival significantly improved: 31.5 vs 16.9 months (HR 0.54; P<0.001)
🔶 Objective response rate: 76.1% vs 50.2% with chemotherapy
🔶 Favorable safety profile: grade ≥3 TRAEs 55.1% vs 86.9% with chemo
🔶 Positions ADC + PD-1 combination as a new first-line standard for HER2-expressing advanced urothelial cancer. @DrChoueiri @PGrivasMDPhD
@Sonpavde @TiansterZhang
@DrDanielHeng @Silke_Gillessen
@montypal @drenriquegrande
@shilpaonc @AndreaNecchi @neerajaiims
@NEJM @theNCI @ASCO @myESMO @OncoAlert #MedicalWatchPapers #UrothelialCancer #BladderCancer #HER2 #ADC #Immunotherapy #PrecisionOncology #OncoTwitter
https://t.co/DZKCFrpsVY
$CHRS Anyway, nice! Phase II, enrollment 40. "Immunotherapy (#Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer"
Diamond💎trial in #NasopharyngealCancer shows addition of anti-PD1 #toripalimab and omitting #cisplatin during RT is safe:
✅3yr FFS 88.3 vs 87.6%, vomiting ⬇️⬇️ without cisplatin @OncoAlert @JAMA_current https://t.co/O45oNG7jQ4
💊 Disitamab vedotin combined with #toripalimab has been found to significantly improve PFS and OS for patients with HER2-expressing, locally or advanced metastatic #urothelialcarcinoma in a recent study: https://t.co/BBvIoYE0rF
🇨🇳 #Junshi Biosciences' #toripalimab has been approved in #China for a new indication for 1L treatment of unresectable or metastatic melanoma. This marks the first Chinese homegrown PD-1 mAb approved for 1L immunotherapy of advanced melanoma. The approval is primarily based on positive data from the MELATORCH study (NCT03430297).
It is the 12th indication approved for toripalimab in China.
To date, a total of 12 PD-1 inhibitors have been approved in China, including two imported drugs and 10 domestic ones. However, for 1L immunotherapy of melanoma, previously only Merck’s pembrolizumab had been approved.
#JUNSHI Anunció la Aprobación del #TORIPALIMAB Para Tratar en 1.ª Línea #SMALL_CELL_LUNG_CANCER en #CHINA Con una OS DE 14,6 MESES. Hoy Ha Alcanzado un ACUERDO DE COMERCIALIZACIÓN PARA #EUROPA Con #LEO_PHARMA. ¿NUEVA BALA DE PLATA MUNDIAL #SCLC?
https://t.co/bd0tO56w3z
#pharmamar
8) But 4 anti-PD-1 antibodies have already been approved for NPC in China, #toripalimab (Junshi), #camrelizumab (Hengrui), #penpulimab (Akeso/CTTQ), and #tislelizumab (BeiGene).
#DrReddy's launches immuno-oncology drug #Toripalimab in #India for treating #nasopharyngeal #carcinoma
https://t.co/vAvah1eHJg
Dr. Reddy's launches Toripalimab in India to treat rare form of head & neck cancer
https://t.co/DlNcEKFaQL
#DrReddys #Toripalimab #NasopharyngealCarcinoma #NPC #HeadCancer #NeckCancer #CancerTreatment #Immunotherapy
#CNBCTV18Market | .@drreddys and subsidiaries launched #Toripalimab, the first & only immuno-oncology drug approved for neck and head #cancer in India
#CancerResearch #CancerAwareness #DRREDDY #DRL
https://t.co/O3zU7iN9bI
#DrReddy's along with its subsidiaries, announced the launch of #Toripalimab in #India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
Read more details on the drug here 👇
https://t.co/5OkhX3KXUt
1/🇨🇳 #Junshi Biosciences announced that the latest data from the Phase II clinical study of #toripalimab in combination with gemcitabine as first-line treatment for cisplatin-intolerant R/M NPC has been published in Cell Reports Medicine. https://t.co/LK7Uc3wG8Q
$CHRS #toripalimab Re. Junshi and LS-SCLC phase III, $AZN places an anti-PD-L1 marker ("results in the durvalumab–tremelimumab group remain blinded"). Anti-PD-L1 + anti-CTLA-4 (AZN) versus anti-PD-1 plus anti-BTLA (Junshi). https://t.co/GFPkfznRlK
進行 #軟部肉腫 に対して、マルチキナーゼ阻害薬 #surufatinib と抗PD-1抗体 #toripalimab の併用療法は良好な抗腫瘍効果と安全性プロファイルを示すことが、進行固形がん患者を対象に中国で行われたバスケット試験の結果示されました。
https://t.co/V8cXsVu7Bn
Junshi Biosciences Reports the CHMP’s Positive Opinion of Loqtorzi (Toripalimab) Across Two Indications
#junshibiosciences #loqtorzi #toripalimab #nasopharyngealcarcinoma #oesophagealsquamouscellcarcinoma #regulatory #chmp #positiveopinion
https://t.co/G4dRL1GOQX
No impact on current $CHRS business plan, #Toripalimab gets positive opinion from CHMP. Surprises me that the trade name is LOQTORZI?? NPC and metastatic or recurrent oesophageal squamous cell carcinoma. https://t.co/QrMe2ebx5F
$CHRS #toripalimab "for patients without a major pathological response or a pathological complete response, the HRs for event-free survival of 0.66 and 0.53, respectively, favored toripalimab and are similar to those observed in the KEYNOTE-671 study"... https://t.co/sjRg6C8gbo
Last Seen Hashtags on Sotwe
freeuse
Seen from United States
momson filter:videos
Seen from United States
momsonn
Seen from Turkey
นิยายปราบผีไทย
Seen from France
incestoconmamá
Seen from Peru
putipobre video
Seen from Mexico
sterek
fivemครางเสียว
Seen from Thailand
storeflash
Seen from United Kingdom
kayseripasifgay
Seen from Turkey
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.2M followers
Barack Obama
@barackobama
119.1M followers
Cristiano Ronaldo
@cristiano
112.8M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.3M followers
NASA
@nasa
92.3M followers
Justin Bieber
@justinbieber
91.4M followers
KATY PERRY
@katyperry
89M followers
Taylor Swift
@taylorswift13
82.9M followers
Lady Gaga
@ladygaga
74.4M followers
Virat Kohli
@imvkohli
71.9M followers
Kim Kardashian
@kimkardashian
70.4M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
64.8M followers
Bill Gates
@billgates
64.6M followers
The Ellen Show
@theellenshow
62.4M followers
Selena Gomez
@selenagomez
62M followers
CNN
@cnn
61.8M followers
X
@x
60.8M followers